The protein has a predicted molecular mass of 47.1 kDa after removal of the signal peptide. The apparent molecular mass of KRAS-mFc is approximately 35-55 kDa due to glycosylation.

Konjugat

Unconjugated

Reinheit

> 95%, by SDS-PAGE and Coomassie blue staining.

Produktform

Lyophilized

Konzentration

Reconstitution dependent.

Formulierung

Lyophilized from sterile Phosphate Buffered Saline, pH 7.4. Normally 5%–8% Trehalose is added as a protectant before lyophilization.

Lagerung

Shipped at 4°C. Lyophilized: Store at -20°C to -80°C. Reconstituted: Aliquot and store at -80°C. Product is stable for one year. Avoid freeze/thaw cycles.

Synonyme

c Ki ras2, c Kirsten ras protein, c-K-ras, c-Ki-ras, Cellular c Ki ras2 proto oncogene, Cellular transforming proto oncogene, CFC2, cK Ras, GTPase KRas, K RAS p21 protein, K RAS2A, K RAS2B, K RAS4A, K RAS4B, K-Ras 2, KI RAS, Ki-Ras, KIRSTEN MURINE SARCOMA VIRUS 2, Kirsten rat sarcoma 2 viral (v Ki ras2) oncogene homolog, Kirsten rat sarcoma viral oncogene homolog, KRAS proto oncogene, GTPase, KRAS1, KRAS2, N-terminally processed, NS, NS3, Oncogene KRAS2, p21ras, PR310 c K ras oncogene, PR310 cK ras oncogene, RALD, RASK2, RASK_HUMAN, Transforming protein p21, v Ki ras2 Kirsten rat sarcoma 2 viral oncogene homolog, v Ki ras2 Kirsten rat sarcoma viral oncogene homolog

Haftungsausschluss

Dieses Produkt ist nur für Forschungszwecke bestimmt. Es ist nicht für diagnostische oder therapeutische Zwecke bestimmt.